Mutational biosynthesis of neomycin analogs by a mutant of neomycin-producing Streptomyces fradiae
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Anti-Bacterial Agents biosynthesis chemistry MeSH
- Bacterial Proteins genetics metabolism MeSH
- Molecular Structure MeSH
- Mutation MeSH
- Neomycin analogs & derivatives biosynthesis MeSH
- Streptomyces enzymology genetics metabolism MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- Bacterial Proteins MeSH
- Neomycin MeSH
Neomycin, produced by Streptomyces fradiae, has been widely used for the treatment of bacterial infections in clinical and agricultural applications. In this study, a neomycin nonproducing mutant of S. fradiae was obtained by gene disruption technique for mutational biosynthesis. A crucial gene neoC (neo7) which encodes 2-deoxystreptamine (2-DOS) synthases was disrupted. The mutant could resume producing neomycin in the presence of 2-DOS. Salen derivatives of 2-DOS were synthesized and individually added to cultures of the mutant. Antibacterial activity of the mutasynthesis products against Staphylococcus aureus and four plant pathogenic bacteria (Pseudomonas solanacarum, Erwinia carotovora, Xanthomonas oryzae, and Xanthomonas campestris) was detected quantitatively by Oxford cup method. It is suggested that all 2-DOS derivatives were incorporated by the mutant into new active neomycin analogs except for 2-DOS derivative 2d ((1R,2r,3S,4R,6S)-4,6-bis((E)-3,5-di-tert-butyl-2-hydroxybenzylideneamino)cyclohexane-1,2,3-triol). Neomycin analogs produced by feeding 2-DOS derivative 2a ((1R,2r,3S,4R,6S)-4,6-bis((E)-2 hydroxybenzylideneamino)cyclohexane-1,2,3-triol) to cultures of the mutant displayed a similar antibacterial activity with neomycin produced by wild strain.
See more in PubMed
Antimicrob Agents Chemother. 2002 May;46(5):1546-9 PubMed
Org Biomol Chem. 2005 Apr 21;3(8):1410-8 PubMed
J Antimicrob Chemother. 1984 Jan;13 Suppl A:9-22 PubMed
J Bacteriol. 1948 Feb;55(2):235-40 PubMed
Biochem Biophys Res Commun. 2001 Oct 5;287(4):870-4 PubMed
Science. 1949 Mar 25;109(2830):305-7 PubMed
Folia Microbiol (Praha). 2009;54(2):91-6 PubMed
J Antibiot (Tokyo). 2004 May;57(5):351-4 PubMed
Bioorg Med Chem Lett. 2001 May 7;11(9):1127-31 PubMed
Folia Microbiol (Praha). 2009;54(2):97-104 PubMed
Folia Microbiol (Praha). 2008;53(5):395-401 PubMed
Proc Natl Acad Sci U S A. 1969 May;63(1):198-204 PubMed
Nat Prod Rep. 2006 Dec;23(6):864-74 PubMed
FEBS Lett. 1999 Feb 19;445(1):73-9 PubMed
Science. 1992 Aug 21;257(5073):1064-73 PubMed
J Antibiot (Tokyo). 1974 Dec;27(12):917-21 PubMed
Curr Microbiol. 2003 Sep;47(3):237-43 PubMed
Mol Cells. 2005 Aug 31;20(1):90-6 PubMed
Biochemistry. 2001 Dec 25;40(51):15612-23 PubMed
EMBO J. 2000 Jan 4;19(1):1-9 PubMed
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9791-5 PubMed
